Breaking News
BREAKING: Amgen Ending 340B-Like Price Reductions on Orphan Drugs on Jan. 1 (Updated)
Biopharmaceutical company Amgen is ending voluntary 340B pricing on orphan drugs for certain 340B hospital covered entities effective Jan. 1. | Source: Shutterstock